抗糖尿病疗法和癌症:从长椅到床边
Dimitris Kounatidis1, Natalia G Vallianou2, Irene Karampela3
1Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, Laiko General Hospital, National and Kapustina University of Athens, 11527 Athens, Greece.
Biomolecules
|November 27, 2024
概括
糖尿病药物会影响癌症的进展. 本综述探讨了降血糖药物,包括甲福明和较新的药物,如何影响癌症生物学及其作为癌症治疗辅助药物的潜力.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病 (DM) 是一个重要的癌症风险因素.
- 抗糖尿病疗法对癌症进展有不同的影响.
- 甲胺通过AMPK/mTOR和自途径显示出潜在的抗癌作用.
研究的目的:
- 综合审查降血糖治疗及其癌症影响.
- 评估将抗糖尿病药物与癌症信号和瘤微环境联系起来的分子机制.
- 评估翻译研究和临床试验的现实世界的相关性.
主要方法:
- 对抗糖尿病药物和癌症的实验证据的文献综述.
- 对分子机制 (AMPK/mTOR,自) 和瘤微环境调节的分析.
- 对翻译研究和临床试验数据的评估.
主要成果:
- 甲福明通过AMPK/mTOR和自作用影响癌症.
- 传统疗法 (胰岛素,SUS,DPP-4抑制剂) 的癌症作用尚不确定.
- 新型药物 (GLP-1 RAs,双GLP-1 / GIP,SGLT-2抑制剂) 正在研究抗癌潜力.
结论:
- 抗糖尿病药物,特别是新型药物,需要对癌症调节进行研究.
- 这些药物可能会影响瘤发生和癌症的进展.
- 对抗糖尿病药物作为辅助药物来增强化疗,减少毒性和克服免疫治疗中的耐药性的潜力存在.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Psychoneuroimmunology: Diabetes and Cancer
24
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
24
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174


